HK1061212A1 - Pyranoindazoles and their use for the treatment ofglaucoma - Google Patents

Pyranoindazoles and their use for the treatment ofglaucoma

Info

Publication number
HK1061212A1
HK1061212A1 HK04104368A HK04104368A HK1061212A1 HK 1061212 A1 HK1061212 A1 HK 1061212A1 HK 04104368 A HK04104368 A HK 04104368A HK 04104368 A HK04104368 A HK 04104368A HK 1061212 A1 HK1061212 A1 HK 1061212A1
Authority
HK
Hong Kong
Prior art keywords
pyranoindazoles
ofglaucoma
treatment
treatment ofglaucoma
Prior art date
Application number
HK04104368A
Other languages
English (en)
Inventor
Hwang-Hsing Chen
Jess A May
Bryon S Severns
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of HK1061212A1 publication Critical patent/HK1061212A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK04104368A 2001-06-01 2004-06-16 Pyranoindazoles and their use for the treatment ofglaucoma HK1061212A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29542901P 2001-06-01 2001-06-01
PCT/US2002/016861 WO2002098350A2 (en) 2001-06-01 2002-05-30 Pyranoindazoles and their use for the treatment of glaucoma

Publications (1)

Publication Number Publication Date
HK1061212A1 true HK1061212A1 (en) 2004-09-10

Family

ID=23137684

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104368A HK1061212A1 (en) 2001-06-01 2004-06-16 Pyranoindazoles and their use for the treatment ofglaucoma

Country Status (20)

Country Link
US (2) US6696476B2 (da)
EP (1) EP1392292B1 (da)
JP (1) JP2004535418A (da)
KR (1) KR100626255B1 (da)
CN (1) CN100384417C (da)
AR (1) AR036044A1 (da)
AT (1) ATE318821T1 (da)
AU (1) AU2002305732B2 (da)
BR (1) BR0210241A (da)
CA (1) CA2447480A1 (da)
DE (1) DE60209486T2 (da)
DK (1) DK1392292T3 (da)
ES (1) ES2258631T3 (da)
HK (1) HK1061212A1 (da)
MX (1) MXPA03010807A (da)
PL (1) PL366636A1 (da)
PT (1) PT1392292E (da)
RU (1) RU2273641C2 (da)
WO (1) WO2002098350A2 (da)
ZA (1) ZA200309034B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
DE60117247D1 (de) * 2000-03-31 2006-04-20 Purdue Research Foundation West Lafayette Phosphoramidat-prodrugs
CA2447480A1 (en) * 2001-06-01 2002-12-12 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2002360819A1 (en) * 2001-12-28 2003-07-24 Bayer Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
PL375564A1 (en) * 2002-08-30 2005-11-28 Alcon, Inc. Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
WO2004054572A2 (en) 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
WO2005025568A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
WO2005058911A2 (en) * 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) * 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
JPWO2008016016A1 (ja) * 2006-07-31 2009-12-24 千寿製薬株式会社 アミド化合物を含有する水性液剤
WO2008016989A1 (en) * 2006-08-01 2008-02-07 Alcon Research, Ltd. Process for preparing pyranoindazole serotonergic receptor agonists
WO2008016993A1 (en) * 2006-08-01 2008-02-07 Alcon Research, Ltd. Intermediates and methods for serotonergic agonist synthesis
WO2008028021A2 (en) * 2006-08-31 2008-03-06 Alcon, Inc. Pyranoindazole cyclic carbonates and their use
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
WO2016139960A1 (ja) * 2015-03-05 2016-09-09 株式会社ブリヂストン ゴム組成物、ジエン系重合体の製造方法及びタイヤ
TW201815766A (zh) * 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN112119072A (zh) 2018-03-20 2020-12-22 普莱希科公司 用于ido和tdo调节的化合物和方法，以及其适应症

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
WO1990002553A1 (en) 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
WO1992020338A1 (en) 1991-05-10 1992-11-26 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
AU1928892A (en) 1991-06-21 1993-01-25 Smithkline Beecham Plc Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
TW270114B (da) 1993-10-22 1996-02-11 Hoffmann La Roche
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US5874477A (en) 1994-08-12 1999-02-23 The University Of Hawaii Method of treatment for malaria utilizing serotonin receptor ligands
TW403738B (en) 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
US5998467A (en) 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
AU2104097A (en) 1996-03-13 1997-10-01 Glaxo Group Limited Medicaments comprising 5ht1-like receptor agonists with an increased absorption
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
WO1998018458A1 (en) 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
JP3560986B2 (ja) 1997-01-13 2004-09-02 山之内製薬株式会社 ５―ｈｔ２ｃ受容体作用薬及びアミノアルキルインダゾール誘導体
GB9700899D0 (en) 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
AU727654B2 (en) 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819033D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
JP2002526443A (ja) 1998-09-18 2002-08-20 アルコン ラボラトリーズ， インコーポレーテッド 緑内障治療用セロトニン作動性５ｈｔ２作用物質
JP2002532504A (ja) 1998-12-17 2002-10-02 アメリカン・ホーム・プロダクツ・コーポレイション ５−ｈｔ２ｃ作動薬である２，３，４，４ａ−テトラヒドロ−１ｈ−ピラジノ（１，２−ａ）キノキサリン−５（６ｈ）−オン誘導体
GB9902047D0 (en) 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
CN1370176A (zh) 1999-06-15 2002-09-18 布里斯托尔-迈尔斯斯奎布药品公司 取代的杂环稠合γ－咔啉
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
CA2401959A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 5-hydroxy indazole derivatives for treating glaucoma
AU5256301A (en) * 2000-04-28 2001-11-12 Yamanouchi Pharmaceutical Co., Ltd. Froindazole derivative
CA2447480A1 (en) * 2001-06-01 2002-12-12 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma

Also Published As

Publication number Publication date
AR036044A1 (es) 2004-08-04
US6881749B2 (en) 2005-04-19
ATE318821T1 (de) 2006-03-15
KR20040010669A (ko) 2004-01-31
US6696476B2 (en) 2004-02-24
PT1392292E (pt) 2006-05-31
EP1392292B1 (en) 2006-03-01
RU2003137825A (ru) 2005-04-20
DE60209486T2 (de) 2006-08-03
WO2002098350A3 (en) 2003-02-27
DE60209486D1 (de) 2006-04-27
ES2258631T3 (es) 2006-09-01
CA2447480A1 (en) 2002-12-12
ZA200309034B (en) 2004-07-16
DK1392292T3 (da) 2006-05-29
MXPA03010807A (es) 2004-11-22
KR100626255B1 (ko) 2006-09-21
AU2002305732B2 (en) 2007-02-01
CN100384417C (zh) 2008-04-30
US20040106609A1 (en) 2004-06-03
JP2004535418A (ja) 2004-11-25
PL366636A1 (en) 2005-02-07
US20030171418A1 (en) 2003-09-11
CN1592619A (zh) 2005-03-09
RU2273641C2 (ru) 2006-04-10
WO2002098350A2 (en) 2002-12-12
EP1392292A2 (en) 2004-03-03
BR0210241A (pt) 2004-08-10
EP1392292A4 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
GB0108671D0 (en) Skin treatment
GB0119025D0 (en) Compounds and their therapeutic use
GB0130763D0 (en) Treatment methods
GB0120009D0 (en) Cause and effect diagnosis
EP1367123A4 (en) NEUROTONIN AND ITS USE
GB0031321D0 (en) Treatment
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
GB0128122D0 (en) Therapeutic use
AU2002364385A8 (en) Implantable device and the use thereof
GB0130694D0 (en) Treatment
GB0116837D0 (en) Treatment
GB0109519D0 (en) Nimico treatment
GB0128512D0 (en) Compounds and their therapeutic use
GB0130736D0 (en) Compounds and their therapeutic use
GB0112689D0 (en) Dispenser and treatment means
GB0116969D0 (en) Neuro-phototransduction device and treatment
GB0119193D0 (en) Medical use
GB0110881D0 (en) Medical use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100530